Ann: COR-004/ATL1103 Project Update, page-22

I guess it's just the uncertainty of being stuck back in a rut to progress either of them.

1103 people where crying out for deals for 3 years ? partner finally came and SBBP was deemed the best offer of the supposed 10 on the table - so either way deals take time even if somebody was there today showing interest would likely take 6-12 months before it saw dry ink & if people are unhappy with what was deemed the best deal first time around what does the 2nd best deal look like ?

1102 who knows - people are talking "just around the corner" but it's been waiting 6 years for a partner.

at least they have a bit of bank if they want to sit on their ass and try to wait it out for a partner to appear and step up but it's not enough cash to progress either of them further alone into a Phase IIB or Phase III trials - hazard a guess its the former for both drugs based on small patient numbers in existing data ?

Not sure what data SBBP saw in the animal studies they did with 1103 - did that sway their view ?

Anyway my pick for FDA's response was that they want to see a Phase IIB with more patients and they didn't get the green light to move straight into Phase III > that would have increased the cost significantly. Maybe something in the animal studies ? but i'd punt on the PII VS PIII outcome.